ESR1 and breast cancer: Although ER+/HER2+ breast cancers are not currently eligible for CDK4/6 inhibitor therapy [36], preclinical data have shown that cyclin D1/CDK4/6/pRB axis may be deregulated and represent a key mechanism driving resistance to anti-HER2 therapies [37].